BioCentury
ARTICLE | Clinical News

FIAsp: Phase I data

August 19, 2013 7:00 AM UTC

Novo Nordisk disclosed in its 2Q13 earnings that a double-blind, crossover, U.S. Phase I trial in 42 Type I diabetics showed that continuous subcutaneous infusion of FIAsp via pump for 14 days met the...